Optimizing the Use of Injectable Therapies for Type 2 Diabetes
The Journal of Family Practice. 2013 December;62(12):S1-S32
This supplement was sponsored by Primary Care Education Consortium and Primary Care Metabolic Group and is supported by funding from Novo Nordisk, Inc. It was edited and peer reviewed by The Journal of Family Practice.
Stephen A. Brunton, MD, FAAFP Adjunct Clinical Professor Department of Family Medicine University of North Carolina Chapel Hill, North Carolina Executive Vice President for Education Primary Care Education Consortium Charlotte, North Carolina
Helena W. Rodbard, MD, FACP, MACE Medical Director Endocrinology and Metabolic Consultants Rockville, Maryland Past President, American Association of Clinical Endocrinologists Past President, American College of Endocrinology
Eden M. Miller, DO Executive Director and Co-Founder Diabetes Nation High Lakes Health Care St. Charles Hospital Bend, Oregon
Martha Funnell, MS, RN, CDE Associate Research Scientist Department of Medical Education Michigan Diabetes Research and Training Center Ann Arbor, Michigan
Edward Shahady, MD, FAAFP, ABCL Medical Director Diabetes Master Clinician Program FAFP/F Fernandina Beach, Florida Clinical Professor, Family Medicine University of Miami and University of Florida
The growing importance of self-injectable medications for the treatment of type 2 diabetes mellitus (T2DM) parallels that for other diseases. This is an especially significant trend, since patients are increasingly self-managing their diseases in the outpatient setting. This makes it necessary for primary care physicians to become more familiar with the role and use of injectable agents for T2DM and to overcome the negative perceptions of injectable therapies.
